UBS Group assumed coverage on shares of Akoya Biosciences (NASDAQ:AKYA – Get Rating) in a report published on Thursday, The Fly reports. The firm issued a buy rating and a $14.00 price target on the stock.
Other equities research analysts have also issued reports about the stock. Capital One Financial began coverage on shares of Akoya Biosciences in a report on Thursday, November 3rd. They set an overweight rating and a $19.00 target price on the stock. Stephens began coverage on shares of Akoya Biosciences in a research note on Wednesday, October 5th. They issued an overweight rating and a $16.00 price objective on the stock. Finally, BTIG Research reduced their price objective on shares of Akoya Biosciences to $18.00 in a research note on Tuesday, November 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of Buy and a consensus target price of $17.17.
Get
Akoya Biosciences alerts:
Akoya Biosciences Price Performance
Shares of AKYA opened at $12.51 on Thursday. The business has a 50-day simple moving average of $11.08 and a two-hundred day simple moving average of $12.29. The stock has a market cap of $474.83 million, a PE ratio of -6.76 and a beta of 1.10. Akoya Biosciences has a 12-month low of $8.02 and a 12-month high of $16.57. The company has a quick ratio of 3.11, a current ratio of 3.53 and a debt-to-equity ratio of 0.71.
Akoya Biosciences (NASDAQ:AKYA – Get Rating) last posted its earnings results on Monday, November 7th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.07). Akoya Biosciences had a negative return on equity of 70.53% and a negative net
margin of 99.49%. The business had revenue of $18.85 million for the quarter, compared to the consensus estimate of $17.80 million. Analysts anticipate that Akoya Biosciences will post -1.8 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Akoya Biosciences news, CFO Joseph Driscoll sold 24,613 shares of the company's stock in a transaction on Wednesday, December 14th. The shares were sold at an average price of $12.54, for a total transaction of $308,647.02. Following the transaction, the chief financial officer now owns 12,500 shares in the company, valued at $156,750. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Akoya Biosciences news, Director Garry Ph.D. Nolan sold 3,810 shares of the company's stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $13.31, for a total transaction of $50,711.10. Following the transaction, the director now owns 618,978 shares in the company, valued at $8,238,597.18. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Joseph Driscoll sold 24,613 shares of the company's stock in a transaction on Wednesday, December 14th. The stock was sold at an average price of $12.54, for a total transaction of $308,647.02. Following the transaction, the chief financial officer now owns 12,500 shares in the company, valued at approximately $156,750. The disclosure for this sale can be found here. Insiders have sold a total of 30,523 shares of company stock valued at $387,201 over the last ninety days. 9.20% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of AKYA. Nisa Investment Advisors LLC purchased a new stake in shares of Akoya Biosciences in the second quarter valued at about $26,000. American International Group Inc. raised its holdings in shares of Akoya Biosciences by 10.8% in the second quarter. American International Group Inc. now owns 7,381 shares of the company's stock valued at $95,000 after purchasing an additional 718 shares during the last quarter. BNP Paribas Arbitrage SNC purchased a new stake in shares of Akoya Biosciences in the third quarter valued at about $89,000. JPMorgan Chase & Co. raised its holdings in shares of Akoya Biosciences by 34.0% in the second quarter. JPMorgan Chase & Co. now owns 8,431 shares of the company's stock valued at $108,000 after purchasing an additional 2,138 shares during the last quarter. Finally, MetLife Investment Management LLC purchased a new stake in shares of Akoya Biosciences in the third quarter valued at about $116,000. Institutional investors and hedge funds own 34.61% of the company's stock.
Akoya Biosciences Company Profile
(Get Rating)
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
Further Reading
- Get a free copy of the StockNews.com research report on Akoya Biosciences (AKYA)
- Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
- Bright Green Corporation Future May be Getting Brighter
- Microsoft Fast Integrating AI Into Enterprise & Healthcare Suites
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
